sdf-1a (cat. Search Results


sdf1a  (R&D Systems)
90
R&D Systems sdf1a
Sdf1a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sdf1a/product/R&D Systems
Average 90 stars, based on 1 article reviews
sdf1a - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cxcl12  (Proteintech)
95
Proteintech cxcl12
Cell–cell interactions between CAF subtypes and myeloid cells. A) Boxplot showing the percentage of MKI67 + cells in each cell type within tumor tissues. Each dot corresponds to each sample. B) Boxplot showing the frequency of each CAF subtype in tumors. Each dot corresponds to each sample. C) Heatmap showing the Spearman correlation coefficient between the abundance of CAF subtypes and the proliferation percent of other cells in tumors. Correlation test p values are indicated, *** p < 0.001, ** p < 0.01, and * p < 0.05. D) Cell–cell interaction network showing interactions between CAF subtypes and other cells in tumors. The dot color indicates the cell type, the dot size indicates the interaction number of a given cell type, and the line thickness indicates the interaction number of a given cell type pair. E) Bar plots showing the interaction number of a given cell type. F) Dot plot showing GO terms of ligands and receptors within specific myeloid cells‐CAFs interactions and specific lymphocytes‐CAFs interactions. G) Dot plot showing the expression level of ligand‐receptor gene pair related with chemotaxis and cytokine within myeloid cell‐CAF interactions. The dot color and size indicate the expression levels and statistical significance, respectively. Red words indicate the ligands (row) expressed in the corresponding cell type (column), and blue words indicate the receptors (row) expressed in the corresponding cell type (column). H) Bar plot showing the fold change of neutrophil migration obtained following the addition of the CAFs/NFs or the CM derived from CAFs/NFs in lower chamber after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. * p < 0.05 and *** p < 0.001. I) Neutrophils were treated with or without CXCL4 inhibitor Plerixafor (25 µM). Neutrophil migration assay was performed by adding control medium or culture medium of CAFs into lower champers, or seeding CAFs into lower champers with or without Plerixafor (25 µM). Bar plot showing the fold change of neutrophil migration after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. ** p < 0.01, **** p < 0.0001, and ns, not significant. J) Cartoon depicting <t>CXCL12‐CXCR4</t> as a major interaction axis between CAFs and myeloid cells.
Cxcl12, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cxcl12/product/Proteintech
Average 95 stars, based on 1 article reviews
cxcl12 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
sdf 1α  (R&D Systems)
94
R&D Systems sdf 1α
Cell–cell interactions between CAF subtypes and myeloid cells. A) Boxplot showing the percentage of MKI67 + cells in each cell type within tumor tissues. Each dot corresponds to each sample. B) Boxplot showing the frequency of each CAF subtype in tumors. Each dot corresponds to each sample. C) Heatmap showing the Spearman correlation coefficient between the abundance of CAF subtypes and the proliferation percent of other cells in tumors. Correlation test p values are indicated, *** p < 0.001, ** p < 0.01, and * p < 0.05. D) Cell–cell interaction network showing interactions between CAF subtypes and other cells in tumors. The dot color indicates the cell type, the dot size indicates the interaction number of a given cell type, and the line thickness indicates the interaction number of a given cell type pair. E) Bar plots showing the interaction number of a given cell type. F) Dot plot showing GO terms of ligands and receptors within specific myeloid cells‐CAFs interactions and specific lymphocytes‐CAFs interactions. G) Dot plot showing the expression level of ligand‐receptor gene pair related with chemotaxis and cytokine within myeloid cell‐CAF interactions. The dot color and size indicate the expression levels and statistical significance, respectively. Red words indicate the ligands (row) expressed in the corresponding cell type (column), and blue words indicate the receptors (row) expressed in the corresponding cell type (column). H) Bar plot showing the fold change of neutrophil migration obtained following the addition of the CAFs/NFs or the CM derived from CAFs/NFs in lower chamber after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. * p < 0.05 and *** p < 0.001. I) Neutrophils were treated with or without CXCL4 inhibitor Plerixafor (25 µM). Neutrophil migration assay was performed by adding control medium or culture medium of CAFs into lower champers, or seeding CAFs into lower champers with or without Plerixafor (25 µM). Bar plot showing the fold change of neutrophil migration after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. ** p < 0.01, **** p < 0.0001, and ns, not significant. J) Cartoon depicting <t>CXCL12‐CXCR4</t> as a major interaction axis between CAFs and myeloid cells.
Sdf 1α, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sdf 1α/product/R&D Systems
Average 94 stars, based on 1 article reviews
sdf 1α - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
recombinant human sdf-1a (cxcl12)  (PeproTech)
90
PeproTech recombinant human sdf-1a (cxcl12)
Cell–cell interactions between CAF subtypes and myeloid cells. A) Boxplot showing the percentage of MKI67 + cells in each cell type within tumor tissues. Each dot corresponds to each sample. B) Boxplot showing the frequency of each CAF subtype in tumors. Each dot corresponds to each sample. C) Heatmap showing the Spearman correlation coefficient between the abundance of CAF subtypes and the proliferation percent of other cells in tumors. Correlation test p values are indicated, *** p < 0.001, ** p < 0.01, and * p < 0.05. D) Cell–cell interaction network showing interactions between CAF subtypes and other cells in tumors. The dot color indicates the cell type, the dot size indicates the interaction number of a given cell type, and the line thickness indicates the interaction number of a given cell type pair. E) Bar plots showing the interaction number of a given cell type. F) Dot plot showing GO terms of ligands and receptors within specific myeloid cells‐CAFs interactions and specific lymphocytes‐CAFs interactions. G) Dot plot showing the expression level of ligand‐receptor gene pair related with chemotaxis and cytokine within myeloid cell‐CAF interactions. The dot color and size indicate the expression levels and statistical significance, respectively. Red words indicate the ligands (row) expressed in the corresponding cell type (column), and blue words indicate the receptors (row) expressed in the corresponding cell type (column). H) Bar plot showing the fold change of neutrophil migration obtained following the addition of the CAFs/NFs or the CM derived from CAFs/NFs in lower chamber after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. * p < 0.05 and *** p < 0.001. I) Neutrophils were treated with or without CXCL4 inhibitor Plerixafor (25 µM). Neutrophil migration assay was performed by adding control medium or culture medium of CAFs into lower champers, or seeding CAFs into lower champers with or without Plerixafor (25 µM). Bar plot showing the fold change of neutrophil migration after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. ** p < 0.01, **** p < 0.0001, and ns, not significant. J) Cartoon depicting <t>CXCL12‐CXCR4</t> as a major interaction axis between CAFs and myeloid cells.
Recombinant Human Sdf 1a (Cxcl12), supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human sdf-1a (cxcl12)/product/PeproTech
Average 90 stars, based on 1 article reviews
recombinant human sdf-1a (cxcl12) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human synthetic stromal cell-derived factor 1 (sdf1a) labeled specifically on residue lys64 with alexafluor 647  (Almac Inc)
90
Almac Inc human synthetic stromal cell-derived factor 1 (sdf1a) labeled specifically on residue lys64 with alexafluor 647
Cell–cell interactions between CAF subtypes and myeloid cells. A) Boxplot showing the percentage of MKI67 + cells in each cell type within tumor tissues. Each dot corresponds to each sample. B) Boxplot showing the frequency of each CAF subtype in tumors. Each dot corresponds to each sample. C) Heatmap showing the Spearman correlation coefficient between the abundance of CAF subtypes and the proliferation percent of other cells in tumors. Correlation test p values are indicated, *** p < 0.001, ** p < 0.01, and * p < 0.05. D) Cell–cell interaction network showing interactions between CAF subtypes and other cells in tumors. The dot color indicates the cell type, the dot size indicates the interaction number of a given cell type, and the line thickness indicates the interaction number of a given cell type pair. E) Bar plots showing the interaction number of a given cell type. F) Dot plot showing GO terms of ligands and receptors within specific myeloid cells‐CAFs interactions and specific lymphocytes‐CAFs interactions. G) Dot plot showing the expression level of ligand‐receptor gene pair related with chemotaxis and cytokine within myeloid cell‐CAF interactions. The dot color and size indicate the expression levels and statistical significance, respectively. Red words indicate the ligands (row) expressed in the corresponding cell type (column), and blue words indicate the receptors (row) expressed in the corresponding cell type (column). H) Bar plot showing the fold change of neutrophil migration obtained following the addition of the CAFs/NFs or the CM derived from CAFs/NFs in lower chamber after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. * p < 0.05 and *** p < 0.001. I) Neutrophils were treated with or without CXCL4 inhibitor Plerixafor (25 µM). Neutrophil migration assay was performed by adding control medium or culture medium of CAFs into lower champers, or seeding CAFs into lower champers with or without Plerixafor (25 µM). Bar plot showing the fold change of neutrophil migration after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. ** p < 0.01, **** p < 0.0001, and ns, not significant. J) Cartoon depicting <t>CXCL12‐CXCR4</t> as a major interaction axis between CAFs and myeloid cells.
Human Synthetic Stromal Cell Derived Factor 1 (Sdf1a) Labeled Specifically On Residue Lys64 With Alexafluor 647, supplied by Almac Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human synthetic stromal cell-derived factor 1 (sdf1a) labeled specifically on residue lys64 with alexafluor 647/product/Almac Inc
Average 90 stars, based on 1 article reviews
human synthetic stromal cell-derived factor 1 (sdf1a) labeled specifically on residue lys64 with alexafluor 647 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
quantikine elisa mouse cxcl12 sdf 1a r d systems cat  (R&D Systems)
95
R&D Systems quantikine elisa mouse cxcl12 sdf 1a r d systems cat
Cell–cell interactions between CAF subtypes and myeloid cells. A) Boxplot showing the percentage of MKI67 + cells in each cell type within tumor tissues. Each dot corresponds to each sample. B) Boxplot showing the frequency of each CAF subtype in tumors. Each dot corresponds to each sample. C) Heatmap showing the Spearman correlation coefficient between the abundance of CAF subtypes and the proliferation percent of other cells in tumors. Correlation test p values are indicated, *** p < 0.001, ** p < 0.01, and * p < 0.05. D) Cell–cell interaction network showing interactions between CAF subtypes and other cells in tumors. The dot color indicates the cell type, the dot size indicates the interaction number of a given cell type, and the line thickness indicates the interaction number of a given cell type pair. E) Bar plots showing the interaction number of a given cell type. F) Dot plot showing GO terms of ligands and receptors within specific myeloid cells‐CAFs interactions and specific lymphocytes‐CAFs interactions. G) Dot plot showing the expression level of ligand‐receptor gene pair related with chemotaxis and cytokine within myeloid cell‐CAF interactions. The dot color and size indicate the expression levels and statistical significance, respectively. Red words indicate the ligands (row) expressed in the corresponding cell type (column), and blue words indicate the receptors (row) expressed in the corresponding cell type (column). H) Bar plot showing the fold change of neutrophil migration obtained following the addition of the CAFs/NFs or the CM derived from CAFs/NFs in lower chamber after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. * p < 0.05 and *** p < 0.001. I) Neutrophils were treated with or without CXCL4 inhibitor Plerixafor (25 µM). Neutrophil migration assay was performed by adding control medium or culture medium of CAFs into lower champers, or seeding CAFs into lower champers with or without Plerixafor (25 µM). Bar plot showing the fold change of neutrophil migration after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. ** p < 0.01, **** p < 0.0001, and ns, not significant. J) Cartoon depicting <t>CXCL12‐CXCR4</t> as a major interaction axis between CAFs and myeloid cells.
Quantikine Elisa Mouse Cxcl12 Sdf 1a R D Systems Cat, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/quantikine elisa mouse cxcl12 sdf 1a r d systems cat/product/R&D Systems
Average 95 stars, based on 1 article reviews
quantikine elisa mouse cxcl12 sdf 1a r d systems cat - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
cxcl12/sdf-1a chemoattractant  (Thermo Fisher)
90
Thermo Fisher cxcl12/sdf-1a chemoattractant
Cell–cell interactions between CAF subtypes and myeloid cells. A) Boxplot showing the percentage of MKI67 + cells in each cell type within tumor tissues. Each dot corresponds to each sample. B) Boxplot showing the frequency of each CAF subtype in tumors. Each dot corresponds to each sample. C) Heatmap showing the Spearman correlation coefficient between the abundance of CAF subtypes and the proliferation percent of other cells in tumors. Correlation test p values are indicated, *** p < 0.001, ** p < 0.01, and * p < 0.05. D) Cell–cell interaction network showing interactions between CAF subtypes and other cells in tumors. The dot color indicates the cell type, the dot size indicates the interaction number of a given cell type, and the line thickness indicates the interaction number of a given cell type pair. E) Bar plots showing the interaction number of a given cell type. F) Dot plot showing GO terms of ligands and receptors within specific myeloid cells‐CAFs interactions and specific lymphocytes‐CAFs interactions. G) Dot plot showing the expression level of ligand‐receptor gene pair related with chemotaxis and cytokine within myeloid cell‐CAF interactions. The dot color and size indicate the expression levels and statistical significance, respectively. Red words indicate the ligands (row) expressed in the corresponding cell type (column), and blue words indicate the receptors (row) expressed in the corresponding cell type (column). H) Bar plot showing the fold change of neutrophil migration obtained following the addition of the CAFs/NFs or the CM derived from CAFs/NFs in lower chamber after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. * p < 0.05 and *** p < 0.001. I) Neutrophils were treated with or without CXCL4 inhibitor Plerixafor (25 µM). Neutrophil migration assay was performed by adding control medium or culture medium of CAFs into lower champers, or seeding CAFs into lower champers with or without Plerixafor (25 µM). Bar plot showing the fold change of neutrophil migration after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. ** p < 0.01, **** p < 0.0001, and ns, not significant. J) Cartoon depicting <t>CXCL12‐CXCR4</t> as a major interaction axis between CAFs and myeloid cells.
Cxcl12/Sdf 1a Chemoattractant, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cxcl12/sdf-1a chemoattractant/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
cxcl12/sdf-1a chemoattractant - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
elisa kit for cxcl12  (Cusabio)
90
Cusabio elisa kit for cxcl12
Expression of <t>CXCL12</t> level in the synovium and the wall of blood vessel from rats. Representative immunohistochemical analyses of CXCL12 expression in the (A) synovium and (B) blood vessel walls, illustrating alterations in the joints of each group of rats (magnification, ×400). ODVs of CXCL12 in the (C) synovium and (D) vessel were markedly decreased in rats with AA following administration of CP-25 and MTX (>10 microscopic fields were observed in each section). (E) Levels of CXCL12 in the synovium assessed by ELISA. (F) Representative western blotting demonstrating CXCR4 expression in rat synovium. Western blotting data are expressed as the means ± standard deviation of three independent experiments. **P<0.01 vs. AA group (n=8–10 per group). (G and H) Correlation between pathological alterations in the pannus score and the expression of CXCL12 and CXCR4 in synovium. AA, adjuvant-induced arthritis; CP-25, paeoniflorin-6′-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; MTX, methotrexate; ODV, optical density value.
Elisa Kit For Cxcl12, supplied by Cusabio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa kit for cxcl12/product/Cusabio
Average 90 stars, based on 1 article reviews
elisa kit for cxcl12 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sdf-1a/cxcr12  (GenScript corporation)
90
GenScript corporation sdf-1a/cxcr12
Expression of <t>CXCL12</t> level in the synovium and the wall of blood vessel from rats. Representative immunohistochemical analyses of CXCL12 expression in the (A) synovium and (B) blood vessel walls, illustrating alterations in the joints of each group of rats (magnification, ×400). ODVs of CXCL12 in the (C) synovium and (D) vessel were markedly decreased in rats with AA following administration of CP-25 and MTX (>10 microscopic fields were observed in each section). (E) Levels of CXCL12 in the synovium assessed by ELISA. (F) Representative western blotting demonstrating CXCR4 expression in rat synovium. Western blotting data are expressed as the means ± standard deviation of three independent experiments. **P<0.01 vs. AA group (n=8–10 per group). (G and H) Correlation between pathological alterations in the pannus score and the expression of CXCL12 and CXCR4 in synovium. AA, adjuvant-induced arthritis; CP-25, paeoniflorin-6′-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; MTX, methotrexate; ODV, optical density value.
Sdf 1a/Cxcr12, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sdf-1a/cxcr12/product/GenScript corporation
Average 90 stars, based on 1 article reviews
sdf-1a/cxcr12 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sdf 1a  (Danaher Inc)
86
Danaher Inc sdf 1a
Expression of <t>CXCL12</t> level in the synovium and the wall of blood vessel from rats. Representative immunohistochemical analyses of CXCL12 expression in the (A) synovium and (B) blood vessel walls, illustrating alterations in the joints of each group of rats (magnification, ×400). ODVs of CXCL12 in the (C) synovium and (D) vessel were markedly decreased in rats with AA following administration of CP-25 and MTX (>10 microscopic fields were observed in each section). (E) Levels of CXCL12 in the synovium assessed by ELISA. (F) Representative western blotting demonstrating CXCR4 expression in rat synovium. Western blotting data are expressed as the means ± standard deviation of three independent experiments. **P<0.01 vs. AA group (n=8–10 per group). (G and H) Correlation between pathological alterations in the pannus score and the expression of CXCL12 and CXCR4 in synovium. AA, adjuvant-induced arthritis; CP-25, paeoniflorin-6′-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; MTX, methotrexate; ODV, optical density value.
Sdf 1a, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sdf 1a/product/Danaher Inc
Average 86 stars, based on 1 article reviews
sdf 1a - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier
mouse sdf-1a/cxcl12  (ProSpec)
90
ProSpec mouse sdf-1a/cxcl12
Expression of <t>CXCL12</t> level in the synovium and the wall of blood vessel from rats. Representative immunohistochemical analyses of CXCL12 expression in the (A) synovium and (B) blood vessel walls, illustrating alterations in the joints of each group of rats (magnification, ×400). ODVs of CXCL12 in the (C) synovium and (D) vessel were markedly decreased in rats with AA following administration of CP-25 and MTX (>10 microscopic fields were observed in each section). (E) Levels of CXCL12 in the synovium assessed by ELISA. (F) Representative western blotting demonstrating CXCR4 expression in rat synovium. Western blotting data are expressed as the means ± standard deviation of three independent experiments. **P<0.01 vs. AA group (n=8–10 per group). (G and H) Correlation between pathological alterations in the pannus score and the expression of CXCL12 and CXCR4 in synovium. AA, adjuvant-induced arthritis; CP-25, paeoniflorin-6′-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; MTX, methotrexate; ODV, optical density value.
Mouse Sdf 1a/Cxcl12, supplied by ProSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse sdf-1a/cxcl12/product/ProSpec
Average 90 stars, based on 1 article reviews
mouse sdf-1a/cxcl12 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human sdf 1a elisa human angiopoietin 2 elisa  (R&D Systems)
95
R&D Systems human sdf 1a elisa human angiopoietin 2 elisa
Expression of <t>CXCL12</t> level in the synovium and the wall of blood vessel from rats. Representative immunohistochemical analyses of CXCL12 expression in the (A) synovium and (B) blood vessel walls, illustrating alterations in the joints of each group of rats (magnification, ×400). ODVs of CXCL12 in the (C) synovium and (D) vessel were markedly decreased in rats with AA following administration of CP-25 and MTX (>10 microscopic fields were observed in each section). (E) Levels of CXCL12 in the synovium assessed by ELISA. (F) Representative western blotting demonstrating CXCR4 expression in rat synovium. Western blotting data are expressed as the means ± standard deviation of three independent experiments. **P<0.01 vs. AA group (n=8–10 per group). (G and H) Correlation between pathological alterations in the pannus score and the expression of CXCL12 and CXCR4 in synovium. AA, adjuvant-induced arthritis; CP-25, paeoniflorin-6′-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; MTX, methotrexate; ODV, optical density value.
Human Sdf 1a Elisa Human Angiopoietin 2 Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human sdf 1a elisa human angiopoietin 2 elisa/product/R&D Systems
Average 95 stars, based on 1 article reviews
human sdf 1a elisa human angiopoietin 2 elisa - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


Cell–cell interactions between CAF subtypes and myeloid cells. A) Boxplot showing the percentage of MKI67 + cells in each cell type within tumor tissues. Each dot corresponds to each sample. B) Boxplot showing the frequency of each CAF subtype in tumors. Each dot corresponds to each sample. C) Heatmap showing the Spearman correlation coefficient between the abundance of CAF subtypes and the proliferation percent of other cells in tumors. Correlation test p values are indicated, *** p < 0.001, ** p < 0.01, and * p < 0.05. D) Cell–cell interaction network showing interactions between CAF subtypes and other cells in tumors. The dot color indicates the cell type, the dot size indicates the interaction number of a given cell type, and the line thickness indicates the interaction number of a given cell type pair. E) Bar plots showing the interaction number of a given cell type. F) Dot plot showing GO terms of ligands and receptors within specific myeloid cells‐CAFs interactions and specific lymphocytes‐CAFs interactions. G) Dot plot showing the expression level of ligand‐receptor gene pair related with chemotaxis and cytokine within myeloid cell‐CAF interactions. The dot color and size indicate the expression levels and statistical significance, respectively. Red words indicate the ligands (row) expressed in the corresponding cell type (column), and blue words indicate the receptors (row) expressed in the corresponding cell type (column). H) Bar plot showing the fold change of neutrophil migration obtained following the addition of the CAFs/NFs or the CM derived from CAFs/NFs in lower chamber after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. * p < 0.05 and *** p < 0.001. I) Neutrophils were treated with or without CXCL4 inhibitor Plerixafor (25 µM). Neutrophil migration assay was performed by adding control medium or culture medium of CAFs into lower champers, or seeding CAFs into lower champers with or without Plerixafor (25 µM). Bar plot showing the fold change of neutrophil migration after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. ** p < 0.01, **** p < 0.0001, and ns, not significant. J) Cartoon depicting CXCL12‐CXCR4 as a major interaction axis between CAFs and myeloid cells.

Journal: Advanced Science

Article Title: Transcriptome Landscape of Cancer‐Associated Fibroblasts in Human PDAC

doi: 10.1002/advs.202415196

Figure Lengend Snippet: Cell–cell interactions between CAF subtypes and myeloid cells. A) Boxplot showing the percentage of MKI67 + cells in each cell type within tumor tissues. Each dot corresponds to each sample. B) Boxplot showing the frequency of each CAF subtype in tumors. Each dot corresponds to each sample. C) Heatmap showing the Spearman correlation coefficient between the abundance of CAF subtypes and the proliferation percent of other cells in tumors. Correlation test p values are indicated, *** p < 0.001, ** p < 0.01, and * p < 0.05. D) Cell–cell interaction network showing interactions between CAF subtypes and other cells in tumors. The dot color indicates the cell type, the dot size indicates the interaction number of a given cell type, and the line thickness indicates the interaction number of a given cell type pair. E) Bar plots showing the interaction number of a given cell type. F) Dot plot showing GO terms of ligands and receptors within specific myeloid cells‐CAFs interactions and specific lymphocytes‐CAFs interactions. G) Dot plot showing the expression level of ligand‐receptor gene pair related with chemotaxis and cytokine within myeloid cell‐CAF interactions. The dot color and size indicate the expression levels and statistical significance, respectively. Red words indicate the ligands (row) expressed in the corresponding cell type (column), and blue words indicate the receptors (row) expressed in the corresponding cell type (column). H) Bar plot showing the fold change of neutrophil migration obtained following the addition of the CAFs/NFs or the CM derived from CAFs/NFs in lower chamber after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. * p < 0.05 and *** p < 0.001. I) Neutrophils were treated with or without CXCL4 inhibitor Plerixafor (25 µM). Neutrophil migration assay was performed by adding control medium or culture medium of CAFs into lower champers, or seeding CAFs into lower champers with or without Plerixafor (25 µM). Bar plot showing the fold change of neutrophil migration after 1 h. For each group, n = 7 biological replicates. Data are shown as mean value ± SD. One‐way ANOVA p values are calculated. ** p < 0.01, **** p < 0.0001, and ns, not significant. J) Cartoon depicting CXCL12‐CXCR4 as a major interaction axis between CAFs and myeloid cells.

Article Snippet: Primary antibodies: CXCL12 (Cat# 17402‐1‐AP, Proteintech), PDPN (Cat# ab236529, Abcam), CK18 (Cat# 10830‐1‐AP, Proteintech), ISG15 (Cat# 15981‐1‐AP, Proteintech), α‐SMA (Cat# ab5694, Abcam), COLL1A1 (Cat# 72026, CST), HLA‐DR (Cat# ab20181, Abcam), CD74 (Cat# ab108393, Abcam), FTL (Cat# 10727‐1‐AP, Proteintech), CDCP1 (Cat# ab252947, Abcam), HIF‐1α (Cat# 20960‐1‐AP, Proteintech), LUM (Cat# ab168343, Abcam), CD3 (Cat# ab5690, Abcam), CD19 (Cat# ab31947, Abcam), CD16 (Cat# 16559‐1‐AP, Proteintech), TPSAB1 (Cat# ab151757, Abcam).

Techniques: Expressing, Chemotaxis Assay, Migration, Derivative Assay, Control

Expression of CXCL12 level in the synovium and the wall of blood vessel from rats. Representative immunohistochemical analyses of CXCL12 expression in the (A) synovium and (B) blood vessel walls, illustrating alterations in the joints of each group of rats (magnification, ×400). ODVs of CXCL12 in the (C) synovium and (D) vessel were markedly decreased in rats with AA following administration of CP-25 and MTX (>10 microscopic fields were observed in each section). (E) Levels of CXCL12 in the synovium assessed by ELISA. (F) Representative western blotting demonstrating CXCR4 expression in rat synovium. Western blotting data are expressed as the means ± standard deviation of three independent experiments. **P<0.01 vs. AA group (n=8–10 per group). (G and H) Correlation between pathological alterations in the pannus score and the expression of CXCL12 and CXCR4 in synovium. AA, adjuvant-induced arthritis; CP-25, paeoniflorin-6′-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; MTX, methotrexate; ODV, optical density value.

Journal: Molecular Medicine Reports

Article Title: CP-25 exerts anti-angiogenic effects on a rat model of adjuvant-induced arthritis by promoting GRK2-induced downregulation of CXCR4-ERK1/2 signaling in endothelial cells

doi: 10.3892/mmr.2019.10765

Figure Lengend Snippet: Expression of CXCL12 level in the synovium and the wall of blood vessel from rats. Representative immunohistochemical analyses of CXCL12 expression in the (A) synovium and (B) blood vessel walls, illustrating alterations in the joints of each group of rats (magnification, ×400). ODVs of CXCL12 in the (C) synovium and (D) vessel were markedly decreased in rats with AA following administration of CP-25 and MTX (>10 microscopic fields were observed in each section). (E) Levels of CXCL12 in the synovium assessed by ELISA. (F) Representative western blotting demonstrating CXCR4 expression in rat synovium. Western blotting data are expressed as the means ± standard deviation of three independent experiments. **P<0.01 vs. AA group (n=8–10 per group). (G and H) Correlation between pathological alterations in the pannus score and the expression of CXCL12 and CXCR4 in synovium. AA, adjuvant-induced arthritis; CP-25, paeoniflorin-6′-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; MTX, methotrexate; ODV, optical density value.

Article Snippet: Cell Counting kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies, Inc. An ELISA kit for CXCL12 (cat. no. CSB-E08729r) was purchased from Cusabio, Inc. Antibodies against α-smooth muscle actin (α-SMA) (cat. no. ab32575), CXCR4 (cat. no. ab124824), GRK2 (cat. no. ab228705), ERK1/2 (cat. no. ab79853), phosphorylated (p)-ERK1/2 (cat. no. ab214362), CXCL12 (cat. no. ab9797), and β-actin (cat. no. ab115777) were purchased from Abcam.

Techniques: Expressing, Immunohistochemical staining, Enzyme-linked Immunosorbent Assay, Western Blot, Standard Deviation, Adjuvant

Effects of CP-25 on CXCL12-induced HUVEC proliferation, migration and tube formation. (A-C) Quantitative analysis of HUVEC proliferation, migration and tube formation induced by various concentrations of CXCL12 for 24 h. (D-F) Quantitative analysis of HUVEC proliferation, migration and tube formation following treatment with CXCL12 alone or in combination with CP-25 for 24 h. (G and H) Representative images of the Transwell and tube formation assays of HUVECs (magnification, ×200). Data are expressed as the means ± standard deviation of three independent experiments. # P<0.05, ## P<0.01 vs. control; *P<0.05, **P<0.01 vs. CXCL12. CP-25, paeoniflorin-6′-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4.

Journal: Molecular Medicine Reports

Article Title: CP-25 exerts anti-angiogenic effects on a rat model of adjuvant-induced arthritis by promoting GRK2-induced downregulation of CXCR4-ERK1/2 signaling in endothelial cells

doi: 10.3892/mmr.2019.10765

Figure Lengend Snippet: Effects of CP-25 on CXCL12-induced HUVEC proliferation, migration and tube formation. (A-C) Quantitative analysis of HUVEC proliferation, migration and tube formation induced by various concentrations of CXCL12 for 24 h. (D-F) Quantitative analysis of HUVEC proliferation, migration and tube formation following treatment with CXCL12 alone or in combination with CP-25 for 24 h. (G and H) Representative images of the Transwell and tube formation assays of HUVECs (magnification, ×200). Data are expressed as the means ± standard deviation of three independent experiments. # P<0.05, ## P<0.01 vs. control; *P<0.05, **P<0.01 vs. CXCL12. CP-25, paeoniflorin-6′-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4.

Article Snippet: Cell Counting kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies, Inc. An ELISA kit for CXCL12 (cat. no. CSB-E08729r) was purchased from Cusabio, Inc. Antibodies against α-smooth muscle actin (α-SMA) (cat. no. ab32575), CXCR4 (cat. no. ab124824), GRK2 (cat. no. ab228705), ERK1/2 (cat. no. ab79853), phosphorylated (p)-ERK1/2 (cat. no. ab214362), CXCL12 (cat. no. ab9797), and β-actin (cat. no. ab115777) were purchased from Abcam.

Techniques: Migration, Standard Deviation, Control

Effects of CP-25 on GRK2 and CXCR4 expression in HUVECs treated with CXCL12. Representative images of western blotting of (A) total, (D) cytoplasmic and (G) membrane expression of GRK2 and CXCR4. (B, C, E, F, H and I) Western blotting semi-quantification of GRK2 and CXCR4 expression. Data are expressed as the means ± standard deviation of three independent experiments. # P<0.05, ## P<0.01 vs. control; *P<0.05, **P<0.01 vs. CXCL12. CP-25, paeoniflorin-6′-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; GRK2; G protein-coupled receptor kinase 2.

Journal: Molecular Medicine Reports

Article Title: CP-25 exerts anti-angiogenic effects on a rat model of adjuvant-induced arthritis by promoting GRK2-induced downregulation of CXCR4-ERK1/2 signaling in endothelial cells

doi: 10.3892/mmr.2019.10765

Figure Lengend Snippet: Effects of CP-25 on GRK2 and CXCR4 expression in HUVECs treated with CXCL12. Representative images of western blotting of (A) total, (D) cytoplasmic and (G) membrane expression of GRK2 and CXCR4. (B, C, E, F, H and I) Western blotting semi-quantification of GRK2 and CXCR4 expression. Data are expressed as the means ± standard deviation of three independent experiments. # P<0.05, ## P<0.01 vs. control; *P<0.05, **P<0.01 vs. CXCL12. CP-25, paeoniflorin-6′-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; GRK2; G protein-coupled receptor kinase 2.

Article Snippet: Cell Counting kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies, Inc. An ELISA kit for CXCL12 (cat. no. CSB-E08729r) was purchased from Cusabio, Inc. Antibodies against α-smooth muscle actin (α-SMA) (cat. no. ab32575), CXCR4 (cat. no. ab124824), GRK2 (cat. no. ab228705), ERK1/2 (cat. no. ab79853), phosphorylated (p)-ERK1/2 (cat. no. ab214362), CXCL12 (cat. no. ab9797), and β-actin (cat. no. ab115777) were purchased from Abcam.

Techniques: Expressing, Western Blot, Membrane, Standard Deviation, Control

Effects of CP-25 on ERK1/2 expression in HUVECs treated with CXCL12. (A) Representative images of western blotting of the expression of ERK1/2 and p-ERK1/2. (B and C) Western blotting semi-quantification of ERK1/2 and p-ERK1/2. (D) Ratio of p-ERK/total-ERK. (E) Representative images of western blotting for the co-expression of GRK2 and CXCR4, and GRK2 and p-ERK1/2. (F and G) Western blotting semi-quantification of the binding between GRK2 and CXCR4, and GRK2 and p-ERK1/2. Data are expressed as the means ± standard deviation of three independent experiments. ## P<0.01 vs. control; *P<0.05, **P<0.01 vs. CXCL12. CP-25, paeoniflorin-6‰-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; GRK2; G protein-coupled receptor kinase 2; p, phosphorylated.

Journal: Molecular Medicine Reports

Article Title: CP-25 exerts anti-angiogenic effects on a rat model of adjuvant-induced arthritis by promoting GRK2-induced downregulation of CXCR4-ERK1/2 signaling in endothelial cells

doi: 10.3892/mmr.2019.10765

Figure Lengend Snippet: Effects of CP-25 on ERK1/2 expression in HUVECs treated with CXCL12. (A) Representative images of western blotting of the expression of ERK1/2 and p-ERK1/2. (B and C) Western blotting semi-quantification of ERK1/2 and p-ERK1/2. (D) Ratio of p-ERK/total-ERK. (E) Representative images of western blotting for the co-expression of GRK2 and CXCR4, and GRK2 and p-ERK1/2. (F and G) Western blotting semi-quantification of the binding between GRK2 and CXCR4, and GRK2 and p-ERK1/2. Data are expressed as the means ± standard deviation of three independent experiments. ## P<0.01 vs. control; *P<0.05, **P<0.01 vs. CXCL12. CP-25, paeoniflorin-6‰-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; GRK2; G protein-coupled receptor kinase 2; p, phosphorylated.

Article Snippet: Cell Counting kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies, Inc. An ELISA kit for CXCL12 (cat. no. CSB-E08729r) was purchased from Cusabio, Inc. Antibodies against α-smooth muscle actin (α-SMA) (cat. no. ab32575), CXCR4 (cat. no. ab124824), GRK2 (cat. no. ab228705), ERK1/2 (cat. no. ab79853), phosphorylated (p)-ERK1/2 (cat. no. ab214362), CXCL12 (cat. no. ab9797), and β-actin (cat. no. ab115777) were purchased from Abcam.

Techniques: Expressing, Western Blot, Binding Assay, Standard Deviation, Control

Regulation of CXCR4 activity and signaling. (A) Upon ligand binding, CXCR4 could activate numerous signaling cascades, which may result in increased GRK2 membrane localization, weakening the inhibitory effect of GRK2 on ERK1/2 in the cytoplasm and enhancing ERK1/2 phosphorylation. (B) CP-25 could inhibit ERK1/2 phosphorylation by reducing the membrane localization of GRK2 and enhancing the inhibitory effect of GRK2 on ERK1/2 in the cytoplasm. CP-25, paeoniflorin-6′-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; GRK2; G protein-coupled receptor kinase 2; p, phosphorylated.

Journal: Molecular Medicine Reports

Article Title: CP-25 exerts anti-angiogenic effects on a rat model of adjuvant-induced arthritis by promoting GRK2-induced downregulation of CXCR4-ERK1/2 signaling in endothelial cells

doi: 10.3892/mmr.2019.10765

Figure Lengend Snippet: Regulation of CXCR4 activity and signaling. (A) Upon ligand binding, CXCR4 could activate numerous signaling cascades, which may result in increased GRK2 membrane localization, weakening the inhibitory effect of GRK2 on ERK1/2 in the cytoplasm and enhancing ERK1/2 phosphorylation. (B) CP-25 could inhibit ERK1/2 phosphorylation by reducing the membrane localization of GRK2 and enhancing the inhibitory effect of GRK2 on ERK1/2 in the cytoplasm. CP-25, paeoniflorin-6′-O-benzene sulfonate; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; GRK2; G protein-coupled receptor kinase 2; p, phosphorylated.

Article Snippet: Cell Counting kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies, Inc. An ELISA kit for CXCL12 (cat. no. CSB-E08729r) was purchased from Cusabio, Inc. Antibodies against α-smooth muscle actin (α-SMA) (cat. no. ab32575), CXCR4 (cat. no. ab124824), GRK2 (cat. no. ab228705), ERK1/2 (cat. no. ab79853), phosphorylated (p)-ERK1/2 (cat. no. ab214362), CXCL12 (cat. no. ab9797), and β-actin (cat. no. ab115777) were purchased from Abcam.

Techniques: Activity Assay, Ligand Binding Assay, Membrane, Phospho-proteomics